(-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.

Abstract

Seventy-nine patients with idiopathic Parkinson's disease in various phases of evolution of the clinical picture were studied. All the patients, already under treatment with L-dopa + PDI, were treated with (-)deprenyl at the dose of 10 mg/day orally in two daily administrations. The mean follow-up was 8.7 months (range, 1-29). Overall, 47.6% of the patients improved, 27.4% showed a marked improvement, 38.1% showed evident modifications, and 27.4% worsened. Sixteen patients were excluded from the study for various reasons. In 53.2% of the cases it was possible to reduce the daily L-dopa dose by a mean of 30%. Overall, (-)deprenyl was effective in the treatment of our parkinsonian patients in the various conditions evaluated, and thus constitutes a new therapeutic strategy for Parkinson's disease.

• Authors: P Giovannini, E Martignoni, I Piccolo, C Pacchetti, M P Grassi, G Nappi, T Caraceni
• Journal: Journal of neural transmission. Supplementum (J Neural Transm Suppl) Vol. 22 Pg. 235-46 ( 1986) ISSN: 0303-6995 [Print] Austria
• PMID: 3097258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Phenethylamines
• Selegiline
• Levodopa
• Carboxy-Lyases

Topics

• Adult
• Aged
• Carboxy-Lyases (antagonists & inhibitors)
• Drug Therapy, Combination
• Female
• Humans
• Levodopa (therapeutic use)
• Male
• Middle Aged
• Parkinson Disease (drug therapy, physiopathology)
• Phenethylamines (therapeutic use)
• Selegiline (adverse effects, therapeutic use)